Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response accurately identifies label support for the role of cigarette smoking and that risk is greatest among women older than 35.
Category Scores
Accurate Statements
Loryna is contraindicated in women who "Smoke, if over age 35".
Label 4 CONTRAINDICATIONS (contraindication includes smoke if over age 35; points to boxed warning and 5.1).
"Known risk factors for VTE include smoking."
Label 5.1 Thromboembolic Disorders and Other Vascular Problems (risk factors for VTE include smoking).
The risk is greatest among older (>35 years of age) women who also smoke.
Label 5.1 ("in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke"), consistent with emphasizing >35.
The overall claim is supported.
Combined support from Contraindications (smoking >35) and Warnings/Precautions (increased cerebrovascular risk greatest among older (>35) women who smoke).
Unsupported Statements
Contradictions
Important Omissions
The claim mentions 'serious cardiovascular events'; the provided label excerpts specifically discuss thromboembolic (VTE) and cerebrovascular (stroke) risks rather than using the phrase 'cardiovascular events' broadly.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response reflects labeled contraindication and labeled risk statements tied to smoking and age >35, with no contradictory or fabricated safety guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Terminology broadness: label excerpts provided emphasize VTE and cerebrovascular (stroke) risks rather than explicitly 'serious cardiovascular events' as a single defined category.
Suggested Improvement
Rephrase to mirror the label wording more closely (e.g., increased thromboembolic/VTE and cerebrovascular/stroke risk) while retaining the key point about increased risk among women >35 who smoke.